Cargando…

Management of Corneal Clouding in Patients with Mucopolysaccharidosis

Mucopolysaccharidoses (MPS) are a rare group of lysosomal storage disorders characterized by the accumulation of incompletely degraded glycosaminoglycans (GAGs) in multiple organ systems including the eye. Visual loss occurs in MPS predominantly due to corneal clouding and retinopathy, but the scler...

Descripción completa

Detalles Bibliográficos
Autores principales:	McGrath, Orlaith, Au, Leon, Ashworth, Jane
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8348690/ https://www.ncbi.nlm.nih.gov/pubmed/34362047 http://dx.doi.org/10.3390/jcm10153263

Ejemplares similares

Use of Imaging Technology to Assess the Effect of COVID-19 on Retinal Tissues: A Systematic Review
por: McGrath, Orlaith E., et al.
Publicado: (2022)

Corneal topometric, aberrometric and biomechanical parameters in mucopolysaccharidosis patients
por: Wasielica-Poslednik, Joanna, et al.
Publicado: (2019)

Mucopolysaccharidosis IVA: Diagnosis, Treatment, and Management
por: Sawamoto, Kazuki, et al.
Publicado: (2020)

Cardiac disease in patients with mucopolysaccharidosis: presentation, diagnosis and management
por: Braunlin, Elizabeth A., et al.
Publicado: (2011)

Retinal Microvasculature Image Analysis Using Optical Coherence Tomography Angiography in Patients with Post-COVID-19 Syndrome
por: Noor, Maha, et al.
Publicado: (2023)

Mucopolysaccharidosis VI
por: Valayannopoulos, Vassili, et al.
Publicado: (2010)

Airway Abnormalities in Adult Mucopolysaccharidosis and Development of Salford Mucopolysaccharidosis Airway Score
por: Gadepalli, Chaitanya, et al.
Publicado: (2021)

Anaesthesia and airway management in mucopolysaccharidosis
por: Walker, Robert, et al.
Publicado: (2012)

Mucopolysaccharidosis-Plus Syndrome
por: Vasilev, Filipp, et al.
Publicado: (2020)

Mucopolysaccharidosis Type I
por: Kubaski, Francyne, et al.
Publicado: (2020)

Atypical corneal clouding in mucopolysaccharidoses
por: Stephen, Mary, et al.
Publicado: (2023)

Diagnosis and Management of Mucopolysaccharidosis Type II (Hunter Syndrome) in Poland
por: Żuber, Zbigniew, et al.
Publicado: (2023)

Mucopolysaccharidosis: A broad review
por: Nagpal, Ritu, et al.
Publicado: (2022)

Diagnostic and treatment strategies in mucopolysaccharidosis VI
por: Vairo, Filippo, et al.
Publicado: (2015)

Ocular features in mucopolysaccharidosis: diagnosis and treatment
por: Del Longo, Alessandra, et al.
Publicado: (2018)

Role of elosulfase alfa in mucopolysaccharidosis IVA
por: Regier, Debra S, et al.
Publicado: (2016)

The Interplay of Glycosaminoglycans and Cysteine Cathepsins in Mucopolysaccharidosis
por: David, Alexis, et al.
Publicado: (2023)

Development of a cloud-based Bioinformatics Training Platform
por: Revote, Jerico, et al.
Publicado: (2017)

Novel therapies for mucopolysaccharidosis type III
por: Seker Yilmaz, Berna, et al.
Publicado: (2020)

Mucopolysaccharidosis type II: European recommendations for the diagnosis and multidisciplinary management of a rare disease
por: Scarpa, Maurizio, et al.
Publicado: (2011)

Mucopolysaccharidosis Type VI, an Updated Overview of the Disease
por: D’Avanzo, Francesca, et al.
Publicado: (2021)

Review of the use of idursulfase in the treatment of mucopolysaccharidosis II
por: Burrow, T Andrew, et al.
Publicado: (2008)

Open issues in Mucopolysaccharidosis type I-Hurler
por: Parini, Rossella, et al.
Publicado: (2017)

Mucopolysaccharidosis IVA: Current Disease Models and Drawbacks
por: Leal, Andrés Felipe, et al.
Publicado: (2023)

Mucopolysaccharidosis Type I: Current Treatments, Limitations, and Prospects for Improvement
por: Hampe, Christiane S., et al.
Publicado: (2021)

Managing Corneal Infections: Out with the old, in with the new?
por: Marasini, Sanjay, et al.
Publicado: (2023)

Hearing Loss in Mucopolysaccharidosis
por: Bicalho, Cibele Gomes, et al.
Publicado: (2021)

Diagnosing mucopolysaccharidosis IVA
por: Wood, Timothy C., et al.
Publicado: (2013)

Mucopolysaccharidosis III: Molecular basis and treatment
por: Spahiu, Lidvana, et al.
Publicado: (2021)

Respiratory and sleep disorders in mucopolysaccharidosis
por: Berger, Kenneth I., et al.
Publicado: (2012)

The evaluation of the disease advancement in patients with mucopolysaccharidosis
por: Opoka-Winiarska, Violetta
Publicado: (2014)

Immunological evaluation of patients with mucopolysaccharidosis (MPS)
por: Aranda, Carolina, et al.
Publicado: (2015)

Growth patterns in patients with mucopolysaccharidosis VII
por: Montaño, Adriana M., et al.
Publicado: (2023)

α-L-iduronidase therapy for mucopolysaccharidosis type I
por: Tolar, Jakub, et al.
Publicado: (2008)

Heparan Sulfate, Mucopolysaccharidosis IIIB and Sulfur Metabolism Disorders
por: Kaczor-Kamińska, Marta, et al.
Publicado: (2022)

Mucopolysaccharidosis: What Pediatric Rheumatologists and Orthopedics Need to Know
por: Costi, Stefania, et al.
Publicado: (2022)

Mucopolysaccharidosis Type I: A Review of the Natural History and Molecular Pathology
por: Hampe, Christiane S., et al.
Publicado: (2020)

Airway management in mucopolysaccharidosis: a retrospective case series review
por: Tümer, Murat, et al.
Publicado: (2021)

A systematic review of new advances in the management of mucopolysaccharidosis VI (Maroteaux-Lamy syndrome): focus on galsulfase
por: El Dib, Regina P, et al.
Publicado: (2009)

Highlight: Sex As Stress Management in Microbes
por: McGrath, Casey
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_b3krprmsfoi3lla45orrvmh9ut